The ASX200 is up nearly a per cent – in a harmonious flow with futures predictions.
Every sector – aside from energy – is in the green.
Materials and industrials are having a particularly strong run, both up around 1.5 per cent.
In company news
South 32 (ASX:S32) is up nearly 6 per cent after confirming it maintained production and cost guidance for all divisions throughout the March quarter except at Australia Manganese – where operations are suspended in the wake of Tropical Cyclone Megan.
Net debt decreased by USD$154 million to USD$937 million during the quarter as South 32 benefited from improved operating performance and a partial unwind in working capital.
S32 has been trading at $3.37.
Boss Energy (ASX:BOE) is up more than 5 per cent after celebrating the production of its first drum of uranium from its Honeymoon project in South Australia.
Moving forward, the company is aiming to lift production and the mine life of the project.
BOE has been trading at $4.83.
Biotech company PYC Therapeutics (ASX:PYC) has revealed its drug – PYC-003- designed to address Autosomal Dominant Polycystic Kidney Disease- has now progressed to human trials.
The disease affects 1 in every 1000 people is characterized by the formation of cysts in the kidneys, which could lead to progressive kidney damage.
PYC-003 has shown promising safety and tolerability profiles in preclinical studies.
PYC has been trading at 9.5 cents.
And Air New Zealand (ASX:AIZ) is up nearly half a per cent despite reducing guidance for FY24.
The airline tips earnings will be more than A$9 million lower and blames ‘softening revenue conditions’ in the fourth quarter, both on the domestic front and in North America.
AIZ has been trading at 52 cents.